Form 4: Seres Therapeutics Director Paul Biondi Acquires Stock Options
SEC Form 4 Filing
Director Paul Biondi acquired 60,000 stock options in Seres Therapeutics, Inc. on April 4, 2024.
Summary
- Paul Biondi, a director of Seres Therapeutics, Inc., acquired 60,000 stock options on April 4, 2024.
- The options have an exercise price of $0.76.
- The options vest fully on the earlier of April 4, 2025, or the day before the company's 2025 annual meeting of shareholders.
- The expiration date for the options is April 3, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports the acquisition of stock options by a director, which is a common occurrence. It doesn't inherently indicate positive or negative sentiment.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/04/2024 | Date of transaction: Paul Biondi acquired 60,000 stock options. |
| 04/04/2025 | Vesting date: Options vest fully on the earlier of this date or the day before the 2025 annual meeting. |
| 04/03/2034 | Expiration date: Options expire on this date. |
| 04/08/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.